Latest News
Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture
April 3, 2024
Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.
EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.
Click here to visit AMGEN Canada and read the full release.
To learn more about osteoporosis treatments visit https://osteoporosis.ca/treatments/
OC MAKES THE NEWS – RECENT ITEMS
Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis.
May 31, 2024
Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]
Dr. Angela Man-Wei Cheung ISCD 2024 Board Announcement
April 19, 2024
Latest News Dr. Angela Man-Wei Cheung ISCD 2024 Board Announcement April 19, 2024 The International Society for Clinical Densitometry (ISCD) is the leading membership organization for professionals working to assess, […]
Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture
April 3, 2024
Latest News Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture April 3, 2024 Amgen Canada has […]